New combo therapy aims to cut relapse in rare lymphoma

This study tests whether adding the drug tislelizumab to standard chemotherapy and radiation can improve outcomes for people with early-stage NK/T-cell lymphoma, a rare blood cancer. About 60 adults aged 18 to 70 will receive the combination treatment. The goal is to see if this approach increases the number of patients whose tumors shrink significantly and helps prevent the cancer from coming back.